Be the first person to write a business review for Althea Technologies, Inc.

Amarillo Biosciences, Inc. company was founded in 1984 and is based in Amarillo, Texas. Amarillo Biosciences, Inc. (AMAR) is engaged in developing biologics for the treatment of human and animal diseases. The Company has a technology for a less toxic method of administration, low-dose oral interferon, in United States Food and Drug Administration (FDA) Phase II clinical trials. The Company has developed a dietary supplement and an interferon alpha lozenge, but, as of December 31, 2008, had not commenced any product commercialization activities. Injectable interferon is an immune modulator used to treat viral and autoimmune diseases and cancer. Orally delivered interferon binds to mucosal cells in the mouth and throat resulting in stimulation of immune mechanisms, and has been shown to activate hundreds of immune system genes in the peripheral blood. As of December 31, 2008, the Company has a Phase II study in progress in the United States to treat oral warts in human immunodeficiency virus-positive (HIV+) patients (Orphan Drug Designation).

Ambrilia Biopharma likes to work with drug candidates when they're still in the early stages of development. Once they hit late stage, the company prefers to license them out for further development. The company is also working to manufacture better formulations of existing drugs to bring in cash. Ambrilia's pipeline includes anti-virals and a handful of oncology drug candidates including generic candidates Octreotide and Goserelin. While it is shifting its focus onto anti-viral drugs, the company is continuing with clinical trials of the two oncology drugs. Mid-shift, however, the company's funds dried up and it filed for bankruptcy protection in the Canadian courts.

American Oriental Bioengineering, Inc. (AOB) is an integrated, pharmaceutical company engaged in the development, manufacture and commercialization of a range of pharmaceutical and healthcare products. The Company’s business comprises prescription pharmaceutical products, over-the-counter (OTC) pharmaceutical products and nutraceutical products. Its pharmaceutical products have been approved by the Chinese State Food and Drug Administration (SFDA). The Company sells its products primarily to hospitals, clinics, pharmacies and retail outlets at over 100,000 locations in all provinces, including rural areas and cities in China. During the year ended December 31, 2008, AOB marketed over 60 pharmaceutical products in China. On October 18, 2008, the Company acquired Nuo Hua Investment Company Limited. On October 20, 2008, the Company acquired GuangXi HuiKe Pharmaceutical Research and Development Co., Ltd.

Amgen GmbH speaks the language of biotech geeks, only with a German accent. Amgen GmbH is a German unit of US-based Amgen, the world's largest biotech company. The subsidiary was established in 1989 to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen and Aranesp, for the treatment of anemia in people with chronic kidney disease; Neupogen and Neulasta, to help restore white blood cell counts for cancer patients; and Enbrel, for the treatment of psoriasis and rheumatoid arthritis.

Amgen Inc. company was founded in 1980 and is based in Thousand Oaks, California. Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. The company has a joint venture with Kirin Holdings Company, Limited to manufacture and market darbepoetin alfa; a co-promotion agreement with Wyeth for marketing and selling of ENBREL; and Johnson & Johnson to commercialize recombinant human erythropoietin as a human therapeutic. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies primarily in the United States, Europe, and Canada.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.